Strata Critical Medical (SRTA) Gross Profit (2021 - 2026)

Strata Critical Medical has disclosed Gross Profit across 6 years of filings, most recently posting $14.1 million for Q1 2026.

• In Q1 2026, Gross Profit rose 100.16% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at $6.8 million (up 113.84% YoY), while the FY2025 annual figure was $41.1 million, up 38.99% from the prior year.
• Gross Profit grew to $14.1 million in Q1 2026, from -$88.1 million in the prior quarter.
• Over the last five years, Gross Profit for SRTA reached as high as $69.2 million in Q2 2025 and fell as low as -$127.6 million in Q4 2023.
• The 5-year median for Gross Profit is $10.4 million (2023), against an average of -$3.8 million.
• Annual changes were most pronounced in 2022 — Gross Profit surged 1582.25% — and 2025, when it tumbled 85.72%.
• A 5-year view of Gross Profit shows it stood at $5.1 million in 2022, then plunged by 2595.7% to -$127.6 million in 2023, then soared by 37.43% to -$79.8 million in 2024, then slipped by 10.42% to -$88.1 million in 2025, then soared by 116.02% to $14.1 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $14.1 million, -$88.1 million, and $11.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.